APP and Alzheimer disease: Cross-validation of the RNA-seq data generated in female APP/PS1 mice treated with CP2 for 14 months against the human dataset available via the accelerating medicine partnership program for AD (AMP-AD) confirmed the translational value of the mouse model and demonstrated that CP2 treatment restored pathways essential for human AD, including inflammation, oxidative stress, and synaptic function [34].